PL2124946T3 - Zastosowanie pochodnych N-metylopirydyniowych do hepatoprotekcji - Google Patents

Zastosowanie pochodnych N-metylopirydyniowych do hepatoprotekcji

Info

Publication number
PL2124946T3
PL2124946T3 PL08719457T PL08719457T PL2124946T3 PL 2124946 T3 PL2124946 T3 PL 2124946T3 PL 08719457 T PL08719457 T PL 08719457T PL 08719457 T PL08719457 T PL 08719457T PL 2124946 T3 PL2124946 T3 PL 2124946T3
Authority
PL
Poland
Prior art keywords
hepatoprotection
methyl pyridinium
pyridinium derivatives
derivatives
methyl
Prior art date
Application number
PL08719457T
Other languages
English (en)
Inventor
Jerzy Gębicki
Andrzej Marcinek
Stefan Chłopicki
Jan Adamus
Original Assignee
Hependo Sp Z O O
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hependo Sp Z O O filed Critical Hependo Sp Z O O
Publication of PL2124946T3 publication Critical patent/PL2124946T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL08719457T 2007-02-28 2008-02-25 Zastosowanie pochodnych N-metylopirydyniowych do hepatoprotekcji PL2124946T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PL381862A PL381862A1 (pl) 2007-02-28 2007-02-28 Zastosowanie związków pirydyniowych i sposób leczenia
EP08719457A EP2124946B1 (en) 2007-02-28 2008-02-25 The use of n-methyl pyridinium derivatives for hepatoprotection
PCT/IB2008/050666 WO2008104920A1 (en) 2007-02-28 2008-02-25 The use of quaternary pyridinium compounds for vasoprotection and/or hepatoprotection

Publications (1)

Publication Number Publication Date
PL2124946T3 true PL2124946T3 (pl) 2012-10-31

Family

ID=39596548

Family Applications (2)

Application Number Title Priority Date Filing Date
PL381862A PL381862A1 (pl) 2007-02-28 2007-02-28 Zastosowanie związków pirydyniowych i sposób leczenia
PL08719457T PL2124946T3 (pl) 2007-02-28 2008-02-25 Zastosowanie pochodnych N-metylopirydyniowych do hepatoprotekcji

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL381862A PL381862A1 (pl) 2007-02-28 2007-02-28 Zastosowanie związków pirydyniowych i sposób leczenia

Country Status (9)

Country Link
US (2) US7893095B2 (pl)
EP (1) EP2124946B1 (pl)
CA (1) CA2714601A1 (pl)
DK (1) DK2124946T3 (pl)
ES (1) ES2388586T3 (pl)
PL (2) PL381862A1 (pl)
PT (1) PT2124946E (pl)
RU (1) RU2477132C2 (pl)
WO (1) WO2008104920A1 (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL364348A1 (pl) 2004-01-12 2005-07-25 PHARMENA Sp.z o.o. Zastosowanie czwartorzędowych soli pirydyniowych jako środka naczynioprotekcyjnego
US8304439B1 (en) 2007-10-12 2012-11-06 Politechnika Lodzka Use of quaternary pyridinium salts as a therapeutic or preventing agent against ionizing radiation-induced damage
WO2009047290A1 (en) * 2007-10-12 2009-04-16 Politechnika Lodzka Use of quaternary pyridinium salts for radioprotection
EP2186419A1 (en) * 2008-11-13 2010-05-19 Tchibo GmbH NMP-containing extract, a method of its production and uses thereof
WO2010055170A1 (en) * 2008-11-17 2010-05-20 Technische Universität München Pyrimidinium derivatives for use in the treatment or prevention of diabetes
WO2012107364A1 (en) * 2011-02-07 2012-08-16 Scipharm Sàrl Novel composition for the treatment of cystic fibrosis
KR101753244B1 (ko) * 2016-02-05 2017-07-11 (주)노터스생명과학 트리고넬린을 유효성분으로 포함하는 숙취 해소 및 간기능 개선용 조성물
ES2967074T3 (es) * 2016-07-18 2024-04-25 Pharmena S A 1 metilnicotinamida para el tratamiento de una enfermedad cardiovascular
WO2024095178A1 (en) 2022-11-01 2024-05-10 Janssen Pharmaceutica Nv Thrombopoietin mimetic for use in the treatment of acute liver failure

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7189865B2 (en) * 2002-07-23 2007-03-13 Attenuon, Llc Thiomolybdate analogues and uses thereof
US7674486B2 (en) * 2003-05-14 2010-03-09 Indus Biotech Pvt. Ltd. Synergistic composition for the treatment of diabetes mellitus
PL364348A1 (pl) * 2004-01-12 2005-07-25 PHARMENA Sp.z o.o. Zastosowanie czwartorzędowych soli pirydyniowych jako środka naczynioprotekcyjnego
US20050267015A1 (en) * 2004-05-04 2005-12-01 Batarseh Kareem I Method of treatment and composition for inhibiting the production of toxic free radical and reactive oxygen species using metalloproteins found in bacteria
WO2006024545A1 (en) * 2004-09-03 2006-03-09 Stichting Voor De Technische Wetenschappen Fused bicyclic natural compounds and their use as inhibitors of parp and parp-mediated inflammatory processes
DE102005029468A1 (de) * 2005-06-24 2006-12-28 Plt Patent & Licence Trading Ltd. Verwendung von Inhibitoren der N-Methyltransferasen in der Therapie des Parkinson-Syndroms
CA2657606A1 (en) * 2006-03-08 2007-09-13 Cortria Corporation Combination therapy with non-selective cox inhibitors to prevent cox-related gastric injuries

Also Published As

Publication number Publication date
US7893095B2 (en) 2011-02-22
US20110118316A1 (en) 2011-05-19
US20080221172A1 (en) 2008-09-11
CA2714601A1 (en) 2008-09-04
EP2124946A1 (en) 2009-12-02
PT2124946E (pt) 2012-08-24
US8377972B2 (en) 2013-02-19
EP2124946B1 (en) 2012-05-23
WO2008104920A1 (en) 2008-09-04
PL381862A1 (pl) 2008-09-01
DK2124946T3 (da) 2012-09-03
RU2009135821A (ru) 2011-04-10
RU2477132C2 (ru) 2013-03-10
ES2388586T3 (es) 2012-10-16

Similar Documents

Publication Publication Date Title
ZA200907414B (en) Substituted Benzoylamino-indan-2-carboxylic acids and related compounds
GB0709031D0 (en) Pharmaceutical compounds
EP2117490A4 (en) DISPOSABLE TRANSPORTER
AU2008272903A8 (en) Treatment for anxiety
IL204563A0 (en) Thiazole derivatives
GB0813087D0 (en) Therapeutic compounds
GB0716532D0 (en) Therapeutic compounds
GB0704932D0 (en) Pharmaceutical compounds
IL210290A0 (en) Use of pyrimidylaminobenzamide derivatives for the treatment of fibrosis
IL202287A0 (en) Therapeutic pyrazolonaphthyridine derivatives
GB0719248D0 (en) Compounds and methods for pharmaceutical use
GB0702537D0 (en) Treatment for excessive adiposity
IL205752A0 (en) Octahydroquinolizines for antidiabetic treatment
GB0708188D0 (en) Therapeutic compounds
GB0702862D0 (en) Therapeutic compounds
ZA201003835B (en) Therapeutic agent for ulcer
GB0708186D0 (en) Therapeutic compounds
TWI348929B (en) Joint
GB0715397D0 (en) Treatment for joint disease
GB0715257D0 (en) Phenylthiazolylpiperazine derivatives for the treatment of nuero degenerative diseases
GB0717573D0 (en) Therapeutic compounds
GB0722401D0 (en) Therapeutic compounds
GB0711886D0 (en) Therapeutic compounds
GB0717569D0 (en) Therapeutic compounds
GB0717568D0 (en) Therapeutic compounds